The New York Times (8/15, Caron) reports, “In July, the Food and Drug Administration posted more shortages in” medications for the treatment of attention-deficit/hyperactivity disorder (AD/HD), and this month, the agency “and the Drug Enforcement Administration took the rare step of issuing a joint public letter acknowledging the shortage and asking manufacturers to increase production.” These actions come as “parents and caregivers across the country are spending hours each month hunting down pharmacies with” AD/HD “medication in stock and asking their doctors to either transfer or rewrite prescriptions.” Meanwhile, “others pay hundreds of dollars out of pocket for name-brand drugs that are sometimes more readily available but, unlike generics, are not covered by their insurance.” Some parents are reporting that the shortage of AD/HD medications is causing “collateral damage to their children’s self-esteem.”
Related Links:
— “The Collateral Damage of A.D.H.D. Drug Shortages,”Christina Caron, The New York Times, August `5, 2023